There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
DOJA Cannabis Company Limited (CSE: DOJA) is pleased to announce that we commenced cultivating our first cannabis strains in July and that the plants have taken well to their new home at DOJA's production facility in British Columbia's Okanagan Valley.
CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
InMed Pharmaceuticals is making bacteria-bred cannabinoids “identical to those found in nature,” sans chemicals or even cannabis.
The studies show that consumers of marijuana tend to make more money, spend more time in the great outdoors, devote more of their time to volunteering and have a generally higher amount of happiness in their lives when compared to people who do not use cannabis. This begs the question, is marijuana the key to happiness?
Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy.
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental health problems.
Medical marijuana has among the highest values in the broader marijuana space, and as with any burgeoning industry, savvy investors are looking for evidence of the market’s core value.
The broader cannabis industry is budding with potential, and the lineup of innovators in this global market provides investors a diverse array of investment opportunities.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product.
ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded a skyrocketing 76% year-over-year operating revenues increase for its fiscal year ended May 31, 2017.
Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company engaged in developing proprietary research as well as products derived from cannabis and hemp oils, has commenced a collaborative relationship with Dr. Laviolette.